- Conditions
- Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue Sarcoma
- Interventions
- Zanzalintinib, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
Recruitment Status
Recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
21991
Shown on this page
12
Current sort
Recently updated
Status scope
Recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1381–1392 of 21,991 matching trials with status Recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
- Interventions
- SAR445877, FOLFOX6, Bevacizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Respiratory Illness, Viral Respiratory Infection
- Interventions
- MBP® Breath Analyzer
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Focal Onset Seizures
- Interventions
- XEN1101, Placebo
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Downey, California • Los Angeles, California + 16 more
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Esophageal Cancer, Appendiceal Cancer
- Interventions
- CYTALUX™ (pafolacianine)
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Cyclophosphamide, Peripheral Blood Stem Cells
- Drug · Other
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 4 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dravet Syndrome
- Interventions
- ION337
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina + 3 more
- Conditions
- Perimenopause, Major Depressive Episode (MDE)
- Interventions
- Not listed
- Lead sponsor
- Van Andel Research Institute
- Other
- Eligibility
- 40 Years to 55 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Grand Rapids, Michigan • Kalamazoo, Michigan • New York, New York
- Conditions
- Neuroendocrine Tumors, Carcinoma, Neuroendocrine
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lumbosacral Radiculopathy
- Interventions
- VER-01, Placebo
- Drug · Other
- Lead sponsor
- Vertanical GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 32
- States / cities
- Mobile, Alabama • Tempe, Arizona • Long Beach, California + 28 more
- Conditions
- Advanced Solid Tumor
- Interventions
- M0324, Pembrolizumab, mFOLFIRINOX
- Biological · Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • New York, New York • San Antonio, Texas
- Conditions
- Prostate Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota